[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR054837A1 - Compuestos inhibidores del virus de la hepatitis c - Google Patents

Compuestos inhibidores del virus de la hepatitis c

Info

Publication number
AR054837A1
AR054837A1 ARP060103033A ARP060103033A AR054837A1 AR 054837 A1 AR054837 A1 AR 054837A1 AR P060103033 A ARP060103033 A AR P060103033A AR P060103033 A ARP060103033 A AR P060103033A AR 054837 A1 AR054837 A1 AR 054837A1
Authority
AR
Argentina
Prior art keywords
alkyl
och2p
cycloalkyl
alkynyl
alkenyl
Prior art date
Application number
ARP060103033A
Other languages
English (en)
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR054837A1 publication Critical patent/AR054837A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se refiere a compuesto inhibidores de HCV, a composiciones que contienen dichos compuestos, y a métodos terapéuticos que incluyen la administracion de dichos compuestos, así como también a los procedimientos e intermediarios utiles para preparar dichos compuestos. Reivindicacion 1: Un compuesto, incluyendo sus enantiomeros de éste, que tiene la estructura general que se muestra en las formulas (1), (2) o (3), o una sal farmacéuticamente aceptable o solvato de éste, donde: R1 es independientemente seleccionado de H, alquilo, alquenilo, alquinilo, arilo, cicloalquilo, heterociclo, halogeno, haloalquilo, alquilsulfonamida, arilsulfonamida, -C(O)NHS(O)2-, o -S(O)2-, opcionalmente sustituido con uno o más A3; R2 está seleccionado de: a) -C(Y1)(A3); b) alquilo C2-10, cicloalquilo C3-7 o alquiloCl-4-cicloalquiloC3-7, donde dicho cicloalquilo y alquil-cicloalquilo puede estar mono-, di- o tri-sustituido con alquilo C1-3; o donde dicho alquilo, cicloalquilo y alquil- cicloalquilo puede estar mono- o di-sustituido con sustituyentes seleccionados de hidroxi y O-alquiloC1-4; o donde cada uno de dichos grupos alquilo puede estar mono-, di- o tri-sustituido con halogeno; o siendo cada uno de dichos grupos cicloalquilo de 5, 6, o 7 miembros, no estando uno o dos de los grupos -CH2 ligados directamente uno del otro, pueden ser reemplazados por -O- de manera que el átomo de O está ligado al átomo de N al cual están unido R2 a través de por lo menos dos átomos de C; o c) fenilo, alquilfenilo C1-3, heteroarilo o alquilheteroarilo C1-3, donde los grupos heteroarilo son de 5 o 6 miembros que tienen 1 a 3 heteroátomos seleccionados de N, O y S, donde dichos grupos fenilo y heteroarilo pueden estar mono- , di- o tri-sustituidos con sustituyentes seleccionados de halogeno, -OH, alquilo C1-4, O-alquiloCl-4, S-alquiloCl-4, -NH2, -NHalquiloCl-4 y -N(alquiloCl-4)2, -CONH2 y -CONH-alquiloCl-4; R3 es PRT, H o alquilo Cl-6; n es independientemente 1 o 2; L está independientemente seleccionado de C o N, con la condicion de que no haya mas de tres N consecutivos, cada uno de ellos opcionalmente sustituido con uno o más A3; Z es O, N o S; Z1 es C o N; Z2a es H, alquilo Cl-l0, alquenilo C2-10, alquinilo C2-10, donde cualquier átomo de carbono puede ser reemplazado con un heteroátomo seleccionado de O, S o N, o Z2a forma opcionalmente un carbociclo o un heterociclo con Q1 o cualquiera A3; Z2b es H, alquilo Cl-6, alquenilo C2-8, alquinilo C2-8; Q1 es alquilo Cl, alquenilo C2-8, o alquinilo C2-8; A3 está independientemente seleccionado de PRT, H, -OH, -C(O)OH, -(CH2)m-, -C(O)O-, - NH-, ciano, alquilo, alquenilo, alquinilo, amino, amido, imido, imino, halogeno, CF3, CH2CF3, cicloalquilo, nitro, arilo, aralquilo, alcoxi, ariloxi, heterociclo, heteroarilo, -C(A2)3, -C(A2)2-C(O)A2, -C(O)A2, -C(O)OA2, -O(A2), -N(A2)2, -S(A2), -CH2P(O)(A2)(OA2), -CH2P(O)(A2)(N(A2)2), -CH2P(O)(OA2)(OA2), -OCH2P(O)(OA2)(OA2), -OCH2P(O)(A2)(OA2), - OCH2P(O)(A2)(N(A2)2), -C(O)OCH2P(O)(OA2)(OA2), -C(O)OCH2P(O)(A2)(OA2), -C(O)OCH2P(O)(A2)(N(A2)2), -CH2P(O)(OA2)(N(A2)2), -OCH2P(O)(OA2)(N(A2)2), -C(O)OCH2P(O)(OA2)(N(A2)2), -CH2P(O)(N(A2)2)(N(A2)2), -C(O)OCH2P(O)(N(A2)2)(N(A2)2), - OCH2P(O)(N(A2)2)(N(A2)2), -(CH2)m-heterociclo, -(CH2)mC(O)Oalquilo, -O-(CH2)m-O-C(O)-Oalquilo, -O-(CH2)r-O-C(O)-(CH2)m-alquilo, -(CH2)mO-C(O)-O-alquilo, -(CH2)mO-C(O)-O-cicloalquilo, -N(H)C(Me)C(O)O-alquilo, o alcoxiarilsulfonamida; donde cada A3 puede estar opcionalmente sustituido con 1 a 4-R1, -P(O)(OA2)(OA2), -P(O)(OA2)(N(A2)2), -P(O)(A2)(OA2), -P(O)(A2)(N(A2)2) o -P(O)(N(A2)2)(N(A2)2), halogeno, alquilo, alquenilo, alquinilo, arilo, carbociclo, heterociclo, aralquilo, arilsulfonamida, arilalquilsulfonamida, ariloxi sulfonamida, ariloxi, alquilsulfonamida, ariloxi arilsulfonamida, alquilsulfonamida, alquiloxi sulfonamida,, alquiloxialquilsulfonamida, -(CH2)m-heterociclo, -(CH2)m-C(O)O-alquilo, -O(CH2)mOC(O)Oalquilo, -O-(CH2)m-O- C(O)-(CH2)m-alquilo, -(CH2)m-O-C(O)-O-alquilo, -(CH2)m-O-C(O)-O-cicloalquilo, -N(H)C(CH3)C(O)O-alquilo, alcoxi, o alcoxi arilsulfonamida, opcionalmente sustituido con -R1, o A3 forma un anillo carbocíclico o heterocíclico con cualquiera de A3 o Q1; Y1 es O, S, N(R2), N(OR2) o N(N(R2)2; A2 es independientemente seleccionado de H, alquilo, alquenilo, alquinilo, amino, aminoácido, alcoxi, ariloxi, ciano, haloalquilo, cicloalquilo, arilo, heteroarilo, alquilsulfonamida, o arilsulfonamida, opcionalmente sustituido con A3; A5 es C o P, opcionalmente sustituido con A3; y m es 0 a 6.
ARP060103033A 2005-07-14 2006-07-14 Compuestos inhibidores del virus de la hepatitis c AR054837A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69909505P 2005-07-14 2005-07-14
US70056005P 2005-07-18 2005-07-18

Publications (1)

Publication Number Publication Date
AR054837A1 true AR054837A1 (es) 2007-07-18

Family

ID=37387401

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103033A AR054837A1 (es) 2005-07-14 2006-07-14 Compuestos inhibidores del virus de la hepatitis c

Country Status (8)

Country Link
US (1) US20070078081A1 (es)
EP (1) EP1904506A1 (es)
JP (1) JP2009501714A (es)
AR (1) AR054837A1 (es)
AU (1) AU2006270264A1 (es)
CA (1) CA2614674A1 (es)
TW (1) TW200738742A (es)
WO (1) WO2007011658A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
JP5249028B2 (ja) * 2005-07-25 2013-07-31 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
KR20090024834A (ko) 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
EP2049474B1 (en) * 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US20090098085A1 (en) * 2006-08-11 2009-04-16 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
US20080107625A1 (en) * 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US8343477B2 (en) * 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US20080107623A1 (en) * 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US7772180B2 (en) * 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) * 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) * 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) * 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7910587B2 (en) * 2007-04-26 2011-03-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl dipeptide hepatitis C virus inhibitors
WO2009005676A2 (en) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Antiviral compounds
KR20100038417A (ko) 2007-06-29 2010-04-14 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
MX2010006210A (es) * 2007-12-05 2010-08-10 Enanta Pharm Inc Inhibidores de serina proteasa de hcv de tripeptido fluorado.
US8202996B2 (en) * 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
WO2009094438A1 (en) * 2008-01-24 2009-07-30 Enanta Pharmaceuticals, Inc. Heteroaryl-containing tripeptide hcv serine protease inhibitors
TW200936131A (en) 2008-02-04 2009-09-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
CN102015652A (zh) 2008-03-20 2011-04-13 益安药业 作为丙型肝炎病毒抑制剂的氟化大环化合物
KR20110005869A (ko) * 2008-04-15 2011-01-19 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규한 마크로사이클릭 억제제
US8163921B2 (en) * 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20090285773A1 (en) * 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20090285774A1 (en) * 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US7964560B2 (en) * 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044023B2 (en) * 2008-05-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US20100080770A1 (en) * 2008-09-29 2010-04-01 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8044087B2 (en) * 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) * 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100272674A1 (en) * 2008-12-04 2010-10-28 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
EP2403860B1 (en) 2009-03-04 2015-11-04 IDENIX Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole as hcv polymerase inhibitors
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
JP2013501068A (ja) 2009-08-05 2013-01-10 アイディニックス ファーマシューティカルズ インコーポレイテッド 大環状セリンプロテアーゼ阻害剤
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
SG181797A1 (en) 2009-12-18 2012-07-30 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
CN103380132B (zh) 2010-12-30 2016-08-31 益安药业 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂
MX2013007677A (es) 2010-12-30 2013-07-30 Abbvie Inc Inhibidores macrociclicos de serina proteasa de hepatitis.
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BR112015007879A2 (pt) 2012-10-19 2017-07-04 Bristol Myers Squibb Co inibidores do vírus da hepatite c
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US20160229866A1 (en) 2013-09-20 2016-08-11 Idenix Pharmaceuticals Inc. Hepatitis c virus inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2015134561A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
EP3114122A1 (en) 2014-03-05 2017-01-11 Idenix Pharmaceuticals LLC Solid forms of a flaviviridae virus inhibitor compound and salts thereof
EA201791460A1 (ru) 2014-12-26 2017-12-29 Эмори Юниверсити N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
WO2019113462A1 (en) 2017-12-07 2019-06-13 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) * 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) * 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
ATE167679T1 (de) * 1990-09-14 1998-07-15 Acad Of Science Czech Republic Wirkstoffvorläufer von phosphonaten
AUPN411195A0 (en) * 1995-07-10 1995-08-03 Cathay Herbal Laboratories Pty Ltd Medicinal composition
AU7890398A (en) * 1996-12-26 1998-07-31 Shionogi & Co., Ltd. Process for the preparation of carbamoyllated imidazole derivatives
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
HUP0303028A3 (en) * 2001-01-31 2005-10-28 Warner Lambert Company Llc Mor Method for carbamoylating alcohols

Also Published As

Publication number Publication date
CA2614674A1 (en) 2007-01-25
US20070078081A1 (en) 2007-04-05
TW200738742A (en) 2007-10-16
JP2009501714A (ja) 2009-01-22
EP1904506A1 (en) 2008-04-02
WO2007011658A1 (en) 2007-01-25
AU2006270264A1 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
AR054837A1 (es) Compuestos inhibidores del virus de la hepatitis c
AR054838A1 (es) Compuestos inhibidores del virus de la hepatitis c
AR061840A1 (es) Compuestos fosfinatos antivirales
CO6251241A2 (es) Compuestos de prolina modificados con actividad anti-vhc
AR050174A1 (es) Derivados de fosfonatos con actividad antiviral. composiciones farmaceuticas
AR067180A1 (es) Compuestos antivirales
AR060405A1 (es) Compuestos organicos y sus usos en tratamientos de infeccion por el virus de hepatitis c
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
PE20090042A1 (es) Analogos de ciclopamina
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20091096A1 (es) Compuestos organicos
AR077977A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
AR068376A1 (es) Amidas heterociclicas utiles para inhibir la via hedgehog.
AR054232A1 (es) Derivados de piridina -2- carboxamida como antagonistas de mglur5
AR072272A1 (es) Piridin-2-onas y piridazin-3-onas sustituidas utiles para el tratamiento de enfermedades autoinmunes e inflamatorias causadas por una activacion aberrante de las celulas b, y composiciones farmaceuticas que las contienen.
HUP0401784A2 (hu) Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények
AR094496A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
AR080187A1 (es) Derivados pirazolicos condensados con heterociclos nitrogenados utiles en el tratamiento de enfermedades inflamatorias, inmunitarias y/o trastornos mieloploliferativos y composiciones farmaceuticas que los contienen.
ES2640911T3 (es) Cicloalquilnitrilpirazolcarboxamidas como inhibidores de la quinasa Janus
AR059512A1 (es) Derivados de piridina -2- carboxamida
AR057769A1 (es) Pirazolo pirimidinas como inhibidores de map quinasa p38, metodos para utilizarlos y composiciones farmaceuticas
AR081653A1 (es) Inhibidores del virus de la hepatitis c
AR091279A1 (es) Inhibidores macrociclicos de virus flaviviridae
AR079334A1 (es) Derivados de oxazin amino
CO6251243A2 (es) Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c

Legal Events

Date Code Title Description
FB Suspension of granting procedure